Results 41 to 50 of about 187,468 (310)

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand   +5 more
wiley   +1 more source

European and US Guideline‐Based Statin Eligibility, Genetically Predicted Coronary Artery Disease, and the Risk of Major Coronary Events

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background A study was designed to investigate whether the coronary artery disease polygenic risk score (CAD‐PRS) may guide lipid‐lowering treatment initiation as well as deferral in primary prevention beyond established clinical risk scores. Methods and
Hanjin Park   +11 more
doaj   +1 more source

Statin non-adherence: clinical consequences and proposed solutions [version 1; referees: 2 approved]

open access: yesF1000Research, 2016
Large controlled clinical trials have demonstrated reductions with statin therapy in cardiovascular events in patients presenting with acute coronary syndromes and stable coronary heart disease and individuals at high risk of a cardiovascular event.
Robert S. Rosenson
doaj   +1 more source

Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study

open access: yesArthritis Research & Therapy, 2021
Objective To evaluate the association between statin use and the risk of developing rheumatoid arthritis (RA) in a large, US case-control study. Methods Using the OptumLabs Data Warehouse, RA cases were identified as patients aged ≥18 years with ≥2 RA ...
Madeline N. Peterson   +5 more
doaj   +1 more source

Modern Management of Asymptomatic Carotid Stenosis: A Meta‐Analysis of CREST‐2, SPACE‐2, and ECST‐2

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Recent randomized trials (CREST‐2, SPACE‐2, and ECST‐2) have compared carotid revascularization (carotid endarterectomy [CEA] or carotid artery stenting [CAS]) plus contemporary medical therapy (CMT) versus CMT alone in asymptomatic carotid stenosis.
Aasim Ali   +14 more
wiley   +1 more source

Statin use in resected, high-risk cutaneous melanoma: A multi-centre retrospective cohort study

open access: yesEJC Skin Cancer
Background: Pre-clinical and clinical studies propose that statins may have chemopreventive effects against cancer, suggesting their possible roles as adjunctive therapies for melanoma. Objective: To investigate the association between regular statin use
Charlie Yue Wang   +6 more
doaj   +1 more source

National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011. [PDF]

open access: yesPLoS ONE, 2016
BACKGROUND:Statin therapy is among the most effective treatments to improve short- and long-term mortality after acute myocardial infarction. The use of statin, and the intensity of their use, has not been described in acute myocardial infarction ...
Lihua Zhang   +14 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Adding ezetimibe to statin therapy: latest evidence and clinical implications

open access: yes, 2018
Background: Statins are the hypolipemic treatment of choice for hyperlipidemia with confirmed atherosclerotic cardiovascular disease (ASCVD) protective effect, proven even in normolipemic patients.
Marija Vavlukis, Ana Vavlukis
core   +1 more source

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. [PDF]

open access: yes, 2016
Statins are the cornerstone of the management of dyslipidaemias and prevention of cardiovascular disease. Although statins are, overall, safe and well tolerated, adverse events can occur and constitute an important barrier to maintaining long-term ...
Windecker, Stephan   +5 more
core   +2 more sources

Home - About - Disclaimer - Privacy